среда, 10 ноября 2010 г.

Facts from AVEO's tivozanib-FOLFOX6 combination Discontinue 1b checking presented at 22nd EORTC-NCI-AACR


AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that fashionable clinical data from a Off 1b dry run evaluating the company's head up by-product runner, tivozanib, a favourably impressive and picky inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a sample chemotherapy regimen, longing be presented during the 22nd Annual Symposium of the European Organization as a service to Into and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) being held November 16-19, 2010 in Berlin, Germany. Additional preclinical facts evaluating tivozanib in AVEO's proprietary tumor models and preclinical facts from the following's anti-fibroblast evolvement representative receptor (FGFR) antibody program determination also be presented.

“Tivozanib is the most strong and particular inhibitor of VEGF receptors 1, 2 and 3, and we rely upon tivozanib's promising tolerability and efficacy portrait suggests the hidden Aciclovir herpes simplex inasmuch as indefinite applicability and combinability with chemotherapies and other targeted agents in multiple tumor types.”

We look assist to sharing these up to date data from our persistent clinical whirl evaluating tivozanib in combination with FOLFOX6 chemotherapy regimen with our peers in the oncology community, said William Slichenmyer, M.D., Sc.M., chief medical manager at AVEO. Tivozanib is the most potent and selective inhibitor of VEGF receptors 1, 2 and 3, and we assume trust to tivozanib's reassuring tolerability and efficacy value suggests the potential payment bright applicability and combinability with chemotherapies and other targeted agents in multiple tumor types.

The schedule through despite AVEO poster presentations at EORTC-NCI-AACR is as follows:

In appendix, Robert Motzer, M.D., attending physician at Cenotaph Sloan-Kettering Cancer Center and lead investigator of TIVO-1, a international Point of view 3 clinical dry run evaluating tivozanib compared to sorafenib in patients with advanced renal cell cancer (RCC), disposition backfire on theretofore presented tivozanib clinical data in patients with advanced RCC at 9:50 a.m. (EST) on November 12, 2010 during the 28th Annual Chemotherapy Foundation Symposium (CFS) at the Marriott Marquis in Unheard of York City.

Комментариев нет: